Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-4

DIMERIX ANNOUNCES POSITIVE TOP-LINE RESULTS IN
PHASE 2a CLINICAL STUDY OF DMX-200 IN FSGS
Highlights
• Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients
• DMX-200 was found to be generally safe and well-tolerated in FSGS patients
• 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo
• A 29% reduction in proteinuria was observed across all patients receiving DMX-200 compared to
placebo
• 29% of patients achieved a >40% reduction in proteinuria on DMX-200 compared to placebo
• Multiple patients from both FSGS and diabetic kidney disease studies continue on DMX-200 via
TGA Special Access Scheme
• Statistically powered Phase 2 study in diabetic kidney disease results due in 4 - 6 weeks